A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
AstraZeneca
Astellas Pharma Inc
Parabilis Medicines, Inc.
Coherus Oncology, Inc.
Ruijin Hospital
Fudan University
I-Mab Biopharma US Limited
University Hospital, Akershus
Duke University
City of Hope Medical Center
UNICANCER
NuCana plc
Memorial Sloan Kettering Cancer Center
ALX Oncology Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
M.D. Anderson Cancer Center
Gruppo Oncologico del Nord-Ovest
Imugene Limited
IGM Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Immodulon Therapeutics Ltd
Tyme, Inc
Taiho Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
Asan Medical Center
University of Cologne
Hoosier Cancer Research Network
National Cancer Institute, Naples
H. Lee Moffitt Cancer Center and Research Institute
Ludwig-Maximilians - University of Munich
Federation Francophone de Cancerologie Digestive
Groupe Oncologie Radiotherapie Tete et Cou
EMD Serono
GSO Global Clinical Research BV
Translational Oncology Research International
Grupo Espanol Multidisciplinario del Cancer Digestivo
Grupo Espanol Multidisciplinario del Cancer Digestivo
Sun Yat-sen University
AIO-Studien-gGmbH
UNICANCER
UNICANCER
University of Florida
American College of Radiology Imaging Network
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
AstraZeneca
Massachusetts General Hospital
Daiichi Sankyo
Eli Lilly and Company